• Sep. 19, 2018 (PDF/79KB)CSR

  Sumitomo Dainippon Pharma Contributes to the 2018 Hokkaido Eastern Iburi Earthquake Relief Efforts in Japan

• Sep. 10, 2018 (PDF/210KB)R&D

  Results of Phase 3 Studies Evaluating Patch Formulation of Atypical Antipsychotic LONASEN Presented at Congress

• Sep. 03, 2018 (PDF/129KB)Corporate

  Sumitomo Dainippon Pharma announces personnel changes

• Sep. 01, 2018 (PDF/228KB)R&D

  FDA Issues a Complete Response Letter for New Drug Application for Dasotraline for the Treatment of ADHD

• Jul. 31, 2018 (PDF/107KB)R&D

  New Drug Application in Japan for Transdermal Patch Formulation of Atypical Antipsychotic LONASEN

more